IGHE and asthma: In randomized clinical trials omalizumab, through its non-steroidal mechanism of action of binding free IgE molecules and preventing activation of the inflammatory cascade, has been shown to reduce asthma exacerbations and thereby reduce the need for oral corticosteroids [8,9].